Physician profile
Robert A Taylor
NPI 1750397360
$5,653.50
in general payments reported to CMS, 2019-2025
27 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $267 · 2021: $378 · 2022: $1,212 · 2023: $746 · 2024: $1,559 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,107.23 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.74 | 2021-2025 | Jardiance |
| Abiomed | $420.76 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $403.24 | 2022-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $399.30 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $373.71 | 2022-2024 | Farxiga |
| Pfizer INC. | $278.92 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $248.73 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $245.59 | 2022-2024 | Camzyos, Eliquis |
| Amgen INC. | $109.10 | 2022-2024 | Repatha |
| Philips North America LLC | $97.63 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Scpharmaceuticals INC. | $86.81 | 2023-2024 | |
| Cardiva Medical, INC. | $54.08 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $53.13 | 2023-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $46.02 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.76 | 2022-2023 | Lifevest |
| Grifols USA, LLC | $38.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $35.60 | 2022-2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $29.06 | 2019 | |
| Novo Nordisk INC | $21.68 | 2025 | Wegovy |
| Cvrx, INC. | $18.57 | 2022-2023 | Barostim Neo System |
| Baxter Healthcare | $16.70 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Tactile Systems Technology INC | $16.37 | 2023 | Flexitouch Plus, Entre Plus |
| Inogen, INC. | $15.55 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.08 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Janssen Biotech, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.